



(12) Translation of
European patent specification

(11) NO/EP 3658192 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 47/68 (2017.01)
A61K 38/19 (2006.01)
A61P 1/00 (2006.01)
A61P 19/02 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.08.16

(80) Date of The European Patent Office Publication of the Granted Patent 2021.04.28

(86) European Application Nr. 18833113.6

(86) European Filing Date 2018.11.29

(87) The European Application's Publication Date 2020.06.03

(30) Priority 2017.12.01, US, 201762593776 P
2017.12.05, US, 201762595054 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Extension States: BA ; ME

(73) Proprietor AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA

(72) Inventor HOBSON, Adrian D., 25 Holman Street, Shrewsbury, Massachusetts 01545, USA
MCPHERSON, Michael J., 287 Pillsbury Road, Ashby, Massachusetts 01431, USA
WAEGELL, Wendy, 7 Rice Corner Road, Brookfield, Massachusetts 01506, USA
GOESS, Christian, 112 Mashapaug Road, Sturbridge, Massachusetts 01566, USA
HERNANDEZ, Axel, Jr., 14 Laurie Lane, Charlton, Massachusetts 01507, USA
WANG, Lu, 14 Stratton Way, Northborough, Massachusetts 01532, USA
WANG, Lu, 12 Nipmuck Drive, Westborough, Massachusetts 01581, USA
MARVIN, Christopher C., 242 Braxton Way, Grayslake, Illinois 60030, USA
SANTORA, Ling C., 7 Thoreau Circle, Shrewsbury, Massachusetts 01545, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF**

(56) References
Cited: WO-A1-2015/153401
WO-A1-2017/210471
PATEL TORAL ET AL: "Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis", DERMATOLOGIC THERAPY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 17, no. 5, 1 January 2004 (2004-01-01), pages 427-431, XP002477489, ISSN: 1396-0296, DOI:

10.1111/J.1396-0296.2004.04045.X


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. Antistoffmedikament-konjugat som omfatter:

(a) et anti-TNF α -antistoff som omfatter en tung kjede med SEQ ID NO: 3 og en lett kjede med SEQ ID NO: 4; og


5 (b) en glukokortikoidreseptor-agonist som omfatter et radikal representert ved formelen:



hvor antistoffet er konjugert til glukokortikoidreseptor-agonisten via en linker representert ved formelen:



10 2. Antistoffmedikament-konjugat ifølge krav 1, ifølge formelen:




hvor A er antistoffet og n er et heltall fra 1-10.

3. Antistoffmedikament-konjugat ifølge krav 2, hvor n er 4.


4. Antistoffmedikament-konjugat ifølge krav 2, hvor n er 2.

15 5. Antistoffmedikament-konjugat ifølge krav 1, med formelen:



hvor A er adalimumab og n er 4.

6. Antistoffmedikament-konjugat ifølge krav 1 med formelen:



5 hvor A er adalimumab og n er 2.